Crescent Biopharma, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +20.7% | -0.5% | +38.3% | +4.4% | +226.9% | -69.9% | -2.3% | -21.7% | -26.0% | -77.1% | +138.8% | |
| – | +42.1% | +27.6% | +26.8% | +22.0% | +35.5% | +11.0% | -11.8% | -36.6% | -7.7% | +34.1% | +178.7% | |
| – | -60.3% | -153.7% | – | – | -1,606.1% | – | -129.6% | – | – | – | -1,254.2% | |
| – | +26.3% | +162.2% | -58.2% | -57.3% | +15.4% | -52.7% | -78.2% | +463.4% | -74.6% | -53.4% | +731,137.5% | |
| – | +26.3% | +162.2% | -58.2% | -57.3% | +15.4% | -52.7% | -78.2% | +463.4% | -74.6% | – | -364,185.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -99.8% | +20,645.1% | +381.3% | +13.6% | -99.7% | +4,294.1% | -40.9% | -61.2% | +593.3% | -100.0% | +5,983,301.3% | |
| – | -115.9% | – | – | +2.5% | -160.1% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.